Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation

被引：26

作者：

Crocchiolo, Roberto ^{[1
,2
]}

Canevari, Carla ^{[3
]}

Assanelli, Andrea ^{[1
,2
]}

Lunghi, Francesca ^{[1
]}

Tassara, Michela ^{[1
]}

Stanghellini, Maria Lupo ^{[1
]}

Clerici, Daniela ^{[1
]}

Landoni, Claudio ^{[3
]}

Servida, Paolo ^{[1
]}

Bernardi, Massimo ^{[1
]}

Peccatori, Jacopo ^{[1
]}

Ferreri, Andres ^{[2
,4
]}

Gianolli, Luigi ^{[3
]}

Bordignon, Claudio ^{[1
]}

Caligaris-Cappio, Federico ^{[2
]}

Ciceri, Fabio ^{[1
,2
]}

Fazio, Ferruccio ^{[3
]}

机构：

[1] Ist Sci San Raffaele, Dept Oncol, Haemtol & BMT Unit, I-20132 Milan, Italy

[2] Ist Sci San Raffaele, Dept Oncol, Unit Lymphoid Malignancies, I-20132 Milan, Italy

[3] Ist Sci San Raffaele, Dept Oncol, Div Nucl Med, I-20132 Milan, Italy

[4] Ist Sci San Raffaele, Dept Oncol, Med Oncol Unit, I-20132 Milan, Italy

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 04期

关键词：

(18)FDG-PET; autologous stem cell transplantation; high-dose sequential chemotherapy; lymphoma;

D O I：

10.1080/10428190701885545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the prognostic role of (18)FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation. Median age was 45 years (range: 18 - 69). After a median follow-up of 31 months (range: 8 - 91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse. The 5-year OS is 90% and 55% (p=0.01) in patients with negative and positive pPET, respectively. In conclusion, a positive pPET indicates a poorer outcome after ASCT with respect to a negative pPET; this subset of patients should be considered candidate to more intensive or investigational approaches.

引用

页码：727 / 733

页数：7

共 39 条

[1] CLINICAL-FEATURES AND PROGNOSIS OF FOLLICULAR LARGE-CELL LYMPHOMA - A REPORT FROM THE NEBRASKA-LYMPHOMA-STUDY-GROUP [J].

ANDERSON, JR ;

VOSE, JM ;

BIERMAN, PJ ;

WEISENBURGER, DD ;

SANGER, WG ;

PIERSON, J ;

BAST, M ;

ARMITAGE, JO .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :218-224

[2] Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation [J].

Becherer, A ;

Mitterbauer, M ;

Jaeger, U ;

Kalhs, P ;

Greinix, HT ;

Karanikas, G ;

Pötzi, C ;

Raderer, M ;

Dudczak, R ;

Kletter, K .

LEUKEMIA, 2002, 16 (02) :260-267

[3] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[4] Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome [J].

Corradini, P. ;

Dodero, A. ;

Farina, L. ;

Fanin, R. ;

Patriarca, F. ;

Miceli, R. ;

Matteucci, P. ;

Bregni, M. ;

Scime, R. ;

Narni, F. ;

Pogliani, E. ;

Locasciulli, A. ;

Milani, R. ;

Carniti, C. ;

Bacigalupo, A. ;

Rambaldi, A. ;

Bonifazi, F. ;

Olivieri, A. ;

Gianni, A. M. ;

Tarella, C. .

LEUKEMIA, 2007, 21 (11) :2316-2323

[5]

COX DR, 1972, J R STAT SOC B, V34, P187

[6] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial [J].

Fermé, C ;

Mounier, N ;

Diviné, M ;

Brice, P ;

Stamatoullas, A ;

Reman, O ;

Voillat, L ;

Jaubert, J ;

Lederlin, P ;

Colin, P ;

Berger, F ;

Salles, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :467-475

[7] Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation [J].

Filmont, JE ;

Czernin, J ;

Yap, C ;

Silverman, DHS ;

Quon, A ;

Phelps, ME ;

Emmanouilides, C .

CHEST, 2003, 124 (02) :608-613

[8] The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation [J].

Filmont, Jean-Emmanuel ;

Gisselbrecht, Christian ;

Cuenca, Xavier ;

Deville, Laure ;

Ertault, Marjan ;

Brice, Pauline ;

De Kerviler, Eric ;

Briere, Josette ;

Larghero, Jerome ;

Moretti, Jean-Luc ;

Mounier, Nicolas .

CANCER, 2007, 110 (06) :1361-1369

[9] FDG-PET/CT in re-staging of patients with lymphoma [J].

Freudenberg, LS ;

Antoch, G ;

Schütt, P ;

Beyer, T ;

Jentzen, W ;

Müller, SP ;

Görges, R ;

Nowrousian, MR ;

Bockisch, A ;

Debatin, JF .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (03) :325-329

[10]

Gallamini A, 2006, HAEMATOLOGICA, V91, P475

← 1 2 3 4 →